Importantly, new therapeutic strategies have emerged to restore NAD+ levels in muscle by administration of dietary NAD+ precursors such as NR or NMN46,53,54, and the conversion of these precursors to NAD+ bypasses the rate limited enzyme NAMPT, which is downregulated in by sarcopenia. This evidence concerns the gene NAMPT and sarcopenia.